La maladie de Parkinson au Canada (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Eléments de l'association

Ontario1445
Susan H. Fox72
Ontario Sauf Susan H. Fox" 1411
Susan H. Fox Sauf Ontario" 38
Ontario Et Susan H. Fox 34
Ontario Ou Susan H. Fox 1483
Corpus8669
\n\n\n\n \n

List of bibliographic references

Number of relevant bibliographic references: 34.
Ident.Authors (with country if any)Title
000123 Anthony H V. Schapira [Royaume-Uni] ; Susan H. Fox [Canada] ; Robert A. Hauser ; Joseph Jankovic [États-Unis] ; Wolfgang H. Jost [Allemagne] ; Christopher Kenney [États-Unis] ; Jaime Kulisevsky [Espagne] ; Rajesh Pahwa ; Werner Poewe [Autriche] ; Ravi Anand [Suisse]Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.
000224 Anna Chang [Canada] ; Susan H. Fox [Canada]Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.
000267 Maria Eliza Freitas [Canada] ; Susan H. Fox [Canada]Nondopaminergic treatments for Parkinson's disease: current and future prospects.
000410 Scott A. Norris [États-Unis] ; H A Jinnah [États-Unis] ; Alberto J. Espay [États-Unis] ; Christine Klein [Allemagne] ; Norbert Brüggemann [Allemagne] ; Richard L. Barbano [États-Unis] ; Irene Andonia C. Malaty [États-Unis] ; Ramon L. Rodriguez [États-Unis] ; Marie Vidailhet [France] ; Emmanuel Roze [France] ; Stephen G. Reich [États-Unis] ; Brian D. Berman [États-Unis] ; Mark S. Ledoux [États-Unis] ; Sarah Pirio Richardson [États-Unis] ; Pinky Agarwal [États-Unis] ; Zoltan Mari [États-Unis] ; William G. Ondo [États-Unis] ; Ludy C. Shih [États-Unis] ; Susan H. Fox [Canada] ; Alfredo Berardelli [Italie] ; Claudia M. Testa [États-Unis] ; Florence Ching-Fen Cheng [Australie] ; Daniel Truong [États-Unis] ; Fatta B. Nahab [États-Unis] ; Tao Xie [États-Unis] ; Mark Hallett [États-Unis] ; Ami R. Rosen [États-Unis] ; Laura J. Wright [États-Unis] ; Joel S. Perlmutter [États-Unis]Clinical and demographic characteristics related to onset site and spread of cervical dystonia.
000522 Tom M. Johnston [Canada] ; Susan H. FoxSymptomatic Models of Parkinson's Disease and L-DOPA-Induced Dyskinesia in Non-human Primates.
000582 Kaviraja Udupa [Canada] ; Susan H. Fox [Canada]Placebo effect in Parkinson's disease: Harnessing the mind in the treatment of PD.
000770 Cynthia L. Comella [États-Unis] ; Susan H. Fox [Canada] ; Kailash P. Bhatia [Royaume-Uni] ; Joel S. Perlmutter [États-Unis] ; Hyder A. Jinnah [États-Unis] ; Mateusz Zurowski [Canada] ; William M. Mcdonald [États-Unis] ; Laura Marsh [États-Unis] ; Ami R. Rosen [États-Unis] ; Tracy Waliczek [États-Unis] ; Laura J. Wright [États-Unis] ; Wendy R. Galpern [États-Unis] ; Glenn T. Stebbins [États-Unis]Development of the Comprehensive Cervical Dystonia Rating Scale: Methodology
000794 Camila Catherine Aquino [Canada] ; Susan H. FoxClinical spectrum of levodopa-induced complications.
000927 Ai Huey Tan [Malaisie] ; Sanjiv Mahadeva [Malaisie] ; Abdul Malik Thalha [Malaisie] ; Peter R. Gibson [Australie] ; Chiun Khang Kiew [Malaisie] ; Chia Ming Yeat [Malaisie] ; Sheang Wen Ng [Malaisie] ; Sheau Phing Ang [Malaisie] ; Siew Kian Chow [Malaisie] ; Chong Tin Tan [Malaisie] ; Hoi Sen Yong [Malaisie] ; Connie Marras [Canada] ; Susan H. Fox [Canada] ; Shen-Yang Lim [Malaisie]Small intestinal bacterial overgrowth in Parkinson's disease.
000C31 Barbara Connolly [Canada] ; Susan H. Fox [Canada]Treatment of Cognitive, Psychiatric, and Affective Disorders Associated with Parkinson’s Disease
000D19 Susan H. Fox [Canada]Non-dopaminergic treatments for motor control in Parkinson's disease.
000E81 Tiago A. Mestre [Canada] ; Mateusz Zurowski ; Susan H. Fox5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders.
000E88 Lorraine V. Kalia [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials
001036 Philippe Huot [Canada] ; Susan H. Fox [Canada]The serotonergic system in motor and non-motor manifestations of Parkinson's disease
001057 Susan H. Fox [Canada]Non-dopaminergic Treatments for Motor Control in Parkinson's Disease
001249 Barbara S. Connolly [Canada] ; Susan H. FoxDrug treatments for the neuropsychiatric complications of Parkinson's disease.
001413 Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Tayyeba Darr [Canada] ; Donna Pires [Canada] ; Lili-Naz Hazrati [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]Increased levels of 5‐HT1A receptor binding in ventral visual pathways in Parkinson's disease
001477 Susan H. Fox [Canada] ; Tom H. Johnston [Canada] ; Qin Li [République populaire de Chine] ; Jonathan Brotchie [Canada] ; Erwan Bezard [République populaire de Chine, France]A critique of available scales and presentation of the non‐human primate dyskinesia rating scale
001824 Arpan R. Mehta [Canada, Royaume-Uni] ; Susan H. Fox [Canada] ; Mark Tarnopolsky [Canada] ; Grace Yoon [Canada]Mitochondrial mimicry of multiple system atrophy of the cerebellar subtype
001986 Susan H. Fox [Canada] ; Jonathan M. BrotchieThe MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future.
001B23 Pettarusp M. Wadia [Canada] ; Gamaliel Tan [Canada] ; Renato P. Munhoz [Canada] ; Susan H. Fox [Canada] ; Stephen J. Lewis [Canada] ; Anthony E. Lang [Canada]Surgical correction of kyphosis in patients with camptocormia due to Parkinson's disease: a retrospective evaluation
001C09 Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tayyeba Darr [Canada] ; Lili-Naz Hazrati [Canada] ; Naomi P. Visanji [Canada] ; Donna Pires [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]Increased 5‐HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations
001C83 Benedicte Ballanger [États-Unis] ; Antonio P. Strafella [États-Unis, Canada] ; Thilo Van Eimeren [États-Unis] ; Mateusz Zurowski [États-Unis] ; Pablo M. Rusjan [États-Unis] ; Sylvain Houle [États-Unis] ; Susan H. Fox [États-Unis]Serotonin 2A Receptors and Visual Hallucinations in Parkinson Disease
001C89 Susan H. Fox [Canada] ; Naomi Visanji [Canada] ; Gaby Reyes [Canada] ; Philippe Huot [Canada] ; Jordi Gomez-Ramirez [Canada] ; Tom Johnston [Canada] ; Jonathan M. Brotchie [Canada]Neuropsychiatric Behaviors in the MPTP Marmoset Model of Parkinson's Disease
001D05 Philippe Huot [Canada] ; Tom H. Johnston [Canada] ; Tayyeba Darr [Canada] ; Lili-Naz Hazrati [Canada] ; Naomi P. Visanji [Canada] ; Donna Pires [Canada] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]Increased 5-HT2A Receptors in the Temporal Cortex of Parkinsonian Patients with Visual Hallucinations
001F59 Susan H. Fox [Canada] ; Rosalind Chuang [Canada] ; Jonathan M. Brotchie [Canada]Serotonin and Parkinson's disease: On movement, mood, and madness
002158 Susan H. Fox [Canada] ; Rosalind Chuang ; Jonathan M. BrotchieParkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy.
002166 Susan H. Fox [Canada] ; Jonathan M. Brotchie ; Anthony E. LangNon-dopaminergic treatments in development for Parkinson's disease.
002308 Susan H. Fox [Canada] ; Anthony E. Lang [Canada]Levodopa‐related motor complications—Phenomenology
002373 Naomi P. Visanji [Canada] ; Rob M. A. De Bie [Canada] ; Tom H. Johnston [Canada] ; Andrew C. Mccreary [Pays-Bas] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]The Nociceptin/Orphanin FQ (NOP) Receptor Antagonist J-113397 Enhances the Effects of Levodopa in the MPTP-Lesioned Nonhuman Primate Model of Parkinson's Disease
002419 Cindy Zadikoff [États-Unis, Canada] ; Susan H. Fox [Canada] ; David F. Tang-Wai [Canada] ; Teri Thomsen [Canada] ; Rob M. A. De Bie [Canada, Pays-Bas] ; Pettarusup Wadia [Canada] ; Janis Miyasaki [Canada] ; Sarah Duff-Canning [Canada] ; Anthony E. Lang [Canada] ; Connie Marras [Canada]A Comparison of the Mini Mental State Exam to the Montreal Cognitive Assessment in Identifying Cognitive Deficits in Parkinson's Disease
002671 Teri R. Thomsen [Canada] ; Wendy R. Galpem [Canada] ; Abena Asante [Canada] ; Tamara Arenovich [Canada] ; Susan H. Fox [Canada]Ipratropium Bromide Spray as Treatment for Sialorrhea in Parkinson's Disease
002813 Naomi P. Visanji [Canada] ; Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Donna Pires [Canada] ; Valerie Voon [Canada, États-Unis] ; Jonathan M. Brotchie [Canada] ; Susan H. Fox [Canada]Pharmacological characterization of psychosis‐like behavior in the MPTP‐lesioned nonhuman primate model of Parkinson's disease
002B51 Tom H. Johnston [Canada] ; Joohyung Lee [Canada] ; Jordi Gomez-Ramirez [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada]A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022